Author

P. Geeleher

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Research Focus:cell type annotation· 3 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Approach:genetic perturbation / CRISPR· 2 Assay:scRNA-seq· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1

Frequent Co-Authors

J. Easton· 4 shared M. Pan· 4 shared R. H. Chapple· 4 shared H. Sheppard· 3 shared H.-M. Lee· 3 shared M. A. Dyer· 3 shared S. M. Pruett-Miller· 3 shared T. Chen· 3 shared

Activity by Year

2021-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

J. Easton

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Bone morphogenetic protein (BMP) signaling determines neuroblastoma cell fate and sensitivity to retinoic acid.

M. Pan, Y. Zhang, W. C. Wright, X. Liu, B. Passaia, D. Currier, R. H. Chapple, J. Steele, J. P. Connelly, M. Lu, H.-M. Lee, A. Loughran, L. Yang, B. J. Abraham, S. M. Pruett-Miller, , P. Geeleher

The paper investigates RA's limited effect on primary neuroblastoma tumors but efficacy in clearing bone marrow cells, identifying BMP signaling as a key determinant of cell fate and RA sensitivity.

bioRxiv · May 9, 2024Cancer Biology

A spatial cell atlas of neuroblastoma reveals developmental, epigenetic and spatial axis of tumor heterogeneity

A. G. Patel, O. Ashenberg, N. B. Collins, A. Segerstolpe, S. Jiang, M. Slyper, X. Huang, C. Caraccio, H. Jin, H. Sheppard, K. Xu, T.-C. Chang, B. A. Orr, A. Shirinifard, R. H. Chapple, , S. J. Rodig

This paper creates a spatial cell atlas of neuroblastoma, revealing tumor heterogeneity through multi-omics data and identifying spatial compartmentalization and signaling patterns.

bioRxiv · Jan 7, 2024 · PreprintCancer Biology

An integrated single-cell RNA-seq map of human neuroblastoma tumors and preclinical models uncovers divergent mesenchymal-like gene expression programs.

R. H. Chapple, X. Liu, S. Natarajan, M. I. M. Alexander, Y. Kim, A. G. Patel, C. W. LaFlamme, M. Pan, W. C. Wright, H.-M. Lee, Y. Zhang, M. Lu, S. C. Koo, C. Long, J. Harper, , P. Geeleher

The paper compares mesenchymal-like gene expression programs in neuroblastoma preclinical models and patient tumors using single-cell RNA-seq and identifies chemotherapy-induced changes in PDX and GEMM.

bioRxiv · Apr 13, 2023Cancer Biology

A CRISPR-drug perturbational map for identifying new compounds to combine with commonly used chemotherapeutics.

H.-M. Lee, W. C. Wright, M. Pan, J. Low, D. Currier, J. Fang, S. Singh, S. Nance, I. Delahunty, Y. Kim, R. H. Chapple, Y. Zhang, X. Liu, J. A. Steele, J. Qi, , P. Geeleher

The paper uses CRISPR knockout screens to identify drug combinations that enhance the effectiveness of common chemotherapeutics in neuroblastoma cells.

bioRxiv · Apr 12, 2023Cancer Biology

The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma.

M. Pan, C. Wright, R. Chapple, A. Zubair, M. Sandhu, J. Batchelder, J. Low, K. Blankenship, L. Wang, B. Gordon, P. Archer, S. W. Brady, S. Natarajan, M. Pozsgai, J. Schuetz, , P. Geeleher

This study identifies CX-5461 as a TOP2B inhibitor with selective activity in high-risk neuroblastoma but highlights safety concerns due to TOP2B off-target effects.

bioRxiv · Feb 25, 2021Cancer Biology